Kyrie Eleyson Baden

Dr. Kyrie Eleyson Baden


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
KBKyrie Eleyson Baden
Kyrie Eleyson Baden
HMHalley McClain
Halley McClain
CCCraig Craig
Craig Craig
NGNathan Robert Gibson
Nathan Robert Gibson
Juanita DraimeJuanita Draime
Juanita Draime
ACAleda M. H. Chen
Aleda M. H. Chen
Background/Objectives: S-adenosylmethionine (SAMe) is a natural compound implicated in the treatment of liver dysfunction. In this systematic review, our objective was to determine the efficacy, safety, and optimal dose of SAMe in liver diseases. Methods: Using the PRISMA methodology, we searched PubMed, CINAHL, and Web of Science using key MeSH search terms. For title/abstract screening, full-text review, and data extraction, two independent researchers reviewed articles, and a third researcher resolved conflicts. Data extraction also included a quality assessment of included articles. Results: Of the 1881 non-duplicated studies, 15 articles focusing on SAMe use in the liver were included. All included studies (n = 15) scored a 4 or 5 out of 5 points on the quality assessment, which indicated high study quality. Overall, SAMe was effective in improving liver-related parameters with few adverse events, which were primarily mild, transient gastrointestinal complaints. Conclusions: The most common doses were SAMe 1000 mg or 1200 mg per day with or without another treatment or natural supplement. Future studies are needed to assess long-term efficacy and safety data of SAMe and the optimal route of administration in liver diseases.

24 June 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
KBKyrie Eleyson Baden
Kyrie Eleyson Baden
SHSarah L. Hoeksema
Sarah L. Hoeksema
NGNathan Robert Gibson
Nathan Robert Gibson
DGDivine Gadi
Divine Gadi
CCCraig Craig
Craig Craig
ACAleda M. H. Chen
Aleda M. H. Chen
Background/Objectives: Glucosamine and chondroitin are natural substances often used alone or in combination for conditions affecting the joints. Our objective was to evaluate the efficacy and safety of glucosamine and/or chondroitin supplementation in humans as well as to determine the common dosages used. Methods: A systematic review was conducted using PRISMA methodology. Searches were performed in PubMed and Web of Science and uploaded into Covidence where two independent researchers reviewed articles according to inclusion and exclusion criteria. Quality assessment was performed using the Mixed Methods Appraisal Tool (MMAT). Results: Of the 2013 articles screened, 146 studies were included in our review, with nearly 60% being randomized controlled trials and most conducted in Europe, Asia, or the U.S. Most studies focused on osteoarthritis and joint pain, with over 90% of efficacy studies reporting positive outcomes and most safety studies indicating minimal or no adverse effects. Glucosamine and chondroitin were most commonly administered together at daily doses of 1500 mg and 1200 mg, respectively, and often compared to a placebo or celecoxib. Conclusions: Overall, the evidence suggests that glucosamine and chondroitin are generally effective and well-tolerated, particularly for managing osteoarthritis and joint pain. Consistent dosing strategies and favorable safety profiles across a diverse range of studies support their continued use in clinical practice, but further research is needed related to other disease states.

18 September 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
KBKyrie Eleyson Baden
Kyrie Eleyson Baden
HMHalley McClain
Halley McClain
CCCraig Craig
Craig Craig
NGNathan Robert Gibson
Nathan Robert Gibson
Juanita DraimeJuanita Draime
Juanita Draime
ACAleda M. H. Chen
Aleda M. H. Chen
Background/Objectives: S-adenosylmethionine (SAMe) is a natural compound used to improve mood-related symptoms. Our aim was to determine the efficacy, safety, and optimal dose of SAMe in Central Nervous System (CNS) signs (e.g., mood, behavior). Methods: We conducted a PRISMA-based systematic review by searching PubMed, CINAHL, and Web of Science using MeSH search terms. Articles were independently reviewed by two researchers (with a third resolving conflicts) during title/abstract screening and full-text review. Data were extracted in the same approach, with a quality assessment of included articles. Results: Out of 1881 non-duplicated studies, 36 were included in the review focusing on CNS signs (mood, behavior, sleep). Most studies (n = 32) achieved a 4 or 5 out of 5 points, indicating high study quality. Overall, SAMe was effective in 24 of 36 studies, with adverse events mostly consisting of mild, transient gastrointestinal disturbances. Conclusions: Many patients in these studies did experience improvements in CNS signs from using SAMe alone or in combination with existing therapy. However, future studies are needed to further understand the long-term effects of SAMe in the CNS.

18 June 2025 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
RCRachel N. Chandra
Rachel N. Chandra
KBKyrie Eleyson Baden
Kyrie Eleyson Baden
ACAleda M. H. Chen
Aleda M. H. Chen